Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?

Author： Gil Lizette   Pérez Daniel   Tápanes Rolando   Pérez Jorge   Grune Tilman  

Publisher： Maney Publishing

ISSN： 1743-2928

Source： Redox Report, Vol.10, Iss.3, 2005-06, pp. : 113-119

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 1, 2012-02 ,pp. : 81-86

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Drug Toxicities of Highly Active Antiretroviral Therapy for HumanImmunodeficiency Virus (HIV) Infection

By  

Current Drug Targets, Vol. 4, Iss. 1, 2003-01 ,pp. : 13-22

Bentham Science Publishers

Access to resources Recommend Favorite

Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 2, 2012-04 ,pp. : 161-178

Bentham Science Publishers

Access to resources Recommend Favorite

The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update

By  

Current Medicinal Chemistry, Vol. 13, Iss. 26, 2006-11 ,pp. : 3121-3132

Bentham Science Publishers

Access to resources Recommend Favorite

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection

By Kaplan Susan S   Hicks Charles B  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1573-1585

Informa Healthcare

Access to resources Recommend Favorite